Skip to main content

CORRECTION article

Front. Pharmacol., 20 October 2021
Sec. Ethnopharmacology
Volume 12 - 2021 | https://doi.org/10.3389/fphar.2021.792330

Corrigendum: Isorhamnetin Inhibits Human Gallbladder Cancer Cell Proliferation and Metastasis via PI3K/AKT Signaling Pathway Inactivation

This article is a correction to:

  1. Isorhamnetin Inhibits Human Gallbladder Cancer Cell Proliferation and Metastasis via PI3K/AKT Signaling Pathway Inactivation

    1. Read original article
Tianyu Zhai,,&#x;Tianyu Zhai1,2,3†Xiaoyu Zhang&#x;Xiaoyu Zhang1†Zhenyu HeiZhenyu Hei1Longyang JinLongyang Jin4Chao HanChao Han5Audrey Tsznam KoAudrey Tsznam Ko6Xiaofeng Yu Xiaofeng Yu7*Jiandong Wang,, Jiandong Wang1,2,3*
  • 1Department of General Surgery, Xinhua Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
  • 2Shanghai Research Center of Biliary Tract Disease, Shanghai, China
  • 3Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, China
  • 4Department of Colorectal Surgery, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
  • 5Department of General Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
  • 6Faculty of Medicine, Imperial College London, London, United Kingdom
  • 7Department of General Surgery, People’s Hospital of Gaoxin District, Suzhou, China

A Corrigendum on
Isorhamnetin Inhibits Human Gallbladder Cancer Cell Proliferation and Metastasis via PI3K/AKT Signaling Pathway Inactivation

by Zhai, T., Zhang, X., Hei, Z., Jin, L., Han, C., Ko, A. Z., Yu, X., and Wang J. (2021). Front. Pharmacol. 12:628621. doi: 10.3389/fphar.2021.628621

In the published article, there was an error in the affiliations order. Affiliations 1 and 3 were interchanged, and the superscript numbers 1 and 3 in the authors’ affiliations list were updated accordingly.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: isorhamnetin, gallbladder cancer, tumor progression, PI3K/Akt pathway, apoptosis

Citation: Zhai T, Zhang X, Hei Z, Jin L, Han C, Ko AT, Yu X and Wang J (2021) Corrigendum: Isorhamnetin Inhibits Human Gallbladder Cancer Cell Proliferation and Metastasis via PI3K/AKT Signaling Pathway Inactivation. Front. Pharmacol. 12:792330. doi: 10.3389/fphar.2021.792330

Received: 10 October 2021; Accepted: 11 October 2021;
Published: 20 October 2021.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2021 Zhai, Zhang, Hei, Jin, Han, Ko, Yu and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Xiaofeng Yu, MTM0MDI2ODI2ODdAMTYzLmNvbQ==; Jiandong Wang, d2FuZ2ppYW5kb25nQHhpbmh1YW1lZC5jb20uY24=

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.